[Skip to Navigation]
Sign In
Views 253
Citations 0
Comment & Response
June 24, 2021

Racial/Ethnic Differences in the 21-Gene Recurrence Score Assay Among Women With Breast Cancer—Reply

Author Affiliations
  • 1Division of Hematology/Oncology, University of Illinois at Chicago
  • 2Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago
JAMA Oncol. 2021;7(8):1248-1249. doi:10.1001/jamaoncol.2021.1959

In Reply We thank Long et al and Obeng-Gyasi and Carlos for their thoughtful comments on our investigation using data from the Surveillance, Epidemiology, and End Results (SEER) Oncotype database to compare rates of a high-risk Oncotype DX Breast Recurrence Score (RS) and breast cancer–specific survival between Black and White patients with axillary node–negative, estrogen receptor–positive breast tumors.1 Long et al question whether SEER data are representative of the US population and suggest that we adjust observed estimates using standardized high-risk RS rates. This would indeed produce relative rates that reflect the true population-level difference. Although the cancer registries from which women were sampled are population based, and past investigations have demonstrated that SEER cancer-specific mortality rates for White and Black women with breast cancer were similar to national rates,2 it is possible that our estimates differ from the underlying populations of interest.3 We agree that a population-standardized estimate, if available, would be ideal. However, to the extent that we demonstrated an independent association with high RS by race, we believe that our findings provide valid evidence that Black women disproportionately develop biologically aggressive, estrogen receptor–positive tumors.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words